共 106 条
[1]
Avedissian SN(2019)A review of the clinical pharmacokinetics of polymyxin B Antibiotics (Basel) 8 E31-39
[2]
Liu J(2019)International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), InternationalSociety for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) Pharmacotherapy. 39 10-e01417
[3]
Rhodes NJ(2018)Population pharmacokinetics of polymyxin B in acutely ill adult patients Antimicrob Agents Chemother 62 e01475-e01417
[4]
Tsuji BT(2018)Population pharmacokinetics of intravenous polymyxin B from clinical samples Antimicrob Agents Chemother 62 e01493-531
[5]
Pogue JM(2013)Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens Clin Infect Dis 57 524-167
[6]
Zavascki AP(2008)Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections Diagn Microbiol Infect Dis 60 163-e00418
[7]
Miglis C(2018)Personalizing polymyxin B dosing using an adaptive feedback control algorithm Antimicrob Agents Chemother 62 e00483-1469
[8]
Rhodes NJ(2018)A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators Clin Pharmacokinet 57 1459-686
[9]
Avedissian SN(2019)Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients Eur J Clin Pharmacol 75 677-1259
[10]
Kubin CJ(2019)Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study Eur J Clin Pharmacol 75 1249-694